

Pfizer response to Axios

On background information:

- As of August 31, Pfizer has shipped more than 1.3 billion doses of the Pfizer-BioNTech COVID-19 Vaccine to 125 countries and territories in every region of the world.
- Pfizer is firmly committed to working towards equitable and affordable access for COVID-19 vaccines for all people around the world, actively working with global governments and global health partners with the aim to provide two billion doses to low and middle income countries in 2021 and 2022 – one billion each year.
 - This includes direct supply agreements with individual country governments; an agreement to supply 500 million doses to the U.S. Government at a not-for-profit price, which the government will, in turn, donate to the African Union and the COVAX 92 Advanced Market Commitment (AMC) countries; and a direct supply agreement with COVAX for 40 million doses in 2021.
- Early on, Pfizer determined that the best way to quickly and safely manufacture the Pfizer-BioNTech COVID-19 Vaccine would be to activate its extensive manufacturing network in Europe and the U.S., including thousands of highly skilled workers, to prepare to produce the COVID-19 vaccine for those most in need around the world.
 - When Pfizer began to supply the Pfizer-BioNTech COVID-19 Vaccine its average timeline from start to vial-ready was approximately 110 days. Pfizer reduced that timeline to an average of 60 days, an almost 50% improvement.
 - The Pfizer-BioNTech vaccine contains 280 different components, manufactured in 86 different sites across 19 different countries.
- Pfizer is continuing to expand and enhance its global COVID-19 vaccine supply chain – which includes expanding its existing facilities, adding more suppliers, and bringing on additional Pfizer/BioNTech sites and contract manufacturers around the world to produce the vaccine.
 - To date, Pfizer and BioNTech have nine operational facilities supporting the global Pfizer-BioNTech COVID-19 Vaccine supply chain, including:
 - In the U.S., Pfizer and BioNTech are leveraging the following Pfizer sites:
 - Pfizer Chesterfield, MO (Raw material manufacturing)
 - Pfizer Andover, MA (Drug substance, raw material manufacturing)
 - Pfizer Kalamazoo, MI (Formulation, fill, finish, and distribution)
 - Pfizer McPherson, KS (Fill and finish)
 - Pfizer Pleasant Prairie, WI (Distribution)
 - In Europe, Pfizer and BioNTech are leveraging the following Pfizer and BioNTech sites:
 - Pfizer Puurs, Belgium (Formulation, fill, finish, and distribution)
 - BioNTech Mainz, Germany (Drug substance)
 - BioNTech Marburg, Germany (Drug substance, and formulation)
 - Pfizer Karlsruhe, Germany (Distribution)
 - The majority of what is made and distributed will continue to come from Pfizer and BioNTech facilities – and, with the induction of new Pfizer/BioNTech sites and contract manufacturers sites, the global Pfizer-BioNTech COVID-19 Vaccine supply chain will now span four continents – North America, Europe, Africa, and South America – and include more than 20 manufacturing facilities.
 - Pfizer and BioNTech select contract manufacturers using a rigorous process based on several factors: quality, compliance, safety track record, technical capability, capacity availability, highly trained workforce, project management

abilities, prior working relationship, and commitment to working with flexibility through a fast-paced program.

On the record quote:

“From day one, our goal has been to provide fair and equitable access of the Pfizer-BioNTech COVID-19 Vaccine to everyone, everywhere. To accomplish this, we are continuing to expand and enhance our global COVID-19 vaccine supply chain – and as a result expect to manufacture up to three billion doses of the Pfizer-BioNTech COVID-19 Vaccine in 2021 and four billion doses of the vaccine in 2022 worldwide.”